An estimated 30-70% of providers with the DEA waiver to treat opioid addiction with buprenorphine do not use it. The goal of this webinar is to review common problems encountered in buprenorphine prescribing via case vignettes. Approaches and strategies for these common challenges will be provided.
Recorded June 2, 2016
ASAM and/or CSAM Members: Free
You must register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and choose your purchase option (member/non-member) and click "Add to Cart."
This enduring internet activity is jointly provided by the California Society of Addiction Medicine (CSAM) and the California Health Care Foundation. CSAM is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.